Frequency of apolipoprotein E4 among older compared with younger HIV patients: support for detrimental effect of E4 on survival

Comment

Victor Valcour et al. Proc Natl Acad Sci U S A. 2008.

. 2008 Oct 14;105(41):E66; author reply E67-8.

doi: 10.1073/pnas.0806919105. Epub 2008 Oct 8.

No abstract available

Conflict of interest statement

The authors declare no conflict of interest.

Apolipoprotein (apo) E4 enhances HIV-1 cell entry in vitro, and the APOE epsilon4/epsilon4 genotype accelerates HIV disease progression.
Burt TD, Agan BK, Marconi VC, He W, Kulkarni H, Mold JE, Cavrois M, Huang Y, Mahley RW, Dolan MJ, McCune JM, Ahuja SK. Burt TD, et al. Proc Natl Acad Sci U S A. 2008 Jun 24;105(25):8718-23. doi: 10.1073/pnas.0803526105. Epub 2008 Jun 18. Proc Natl Acad Sci U S A. 2008. PMID: 18562290 Free PMC article.

1. Burt TD, et al. Apolipoprotein (apo) E4 enhances HIV-1 cell entry in vitro, and the APOE ε4/ε4 genotype accelerates HIV disease progression. Proc Natl Acad Sci USA. 2008;105:8718–8723. - PMC - PubMed
1. Valcour V, et al. Age, apolipoprotein E4, and the risk of HIV dementia: The Hawaii Aging with HIV Cohort. J Neuroimmunol. 2004;157:197–202. - PubMed
1. Shiramizu B, et al. Circulating proviral HIV DNA and HIV-associated dementia. AIDS. 2005;19:45–52. - PMC - PubMed